Publications by authors named "Francesco Rech"
Article Synopsis
- - The study explores how pregnancy-related factors, emotional awareness (alexithymia), and depression impact dream experiences in women during their first trimester, suggesting that dreaming helps with emotional regulation during this sensitive period.
- - 118 pregnant women participated in various questionnaires measuring their dream characteristics, emotional awareness, and depression, revealing that older age, prior pregnancies, and depressive symptoms influenced dream recall and nightmares.
- - Findings indicate that higher alexithymia and depressive symptoms are linked to more frequent and distressing nightmares, suggesting a need for targeted support to improve emotional coping strategies in pregnant women; future studies should look into the content of these nightmares for better understanding.
Objectives: Congenital cytomegalovirus (cCMV) infection can be easily prevented by hygienic measures. Up to date the majority of the studies in literature highlighted a reduction in cCMV antenatal counseling and its prevention. Our purpose was to evaluate obstetrics providers' knowledge about cCMV infection, management and the behavioral practices to avoid it.
View Article and Find Full Text PDFPreterm birth is an obstetric condition associated with a high risk of infant mortality and morbidities in both the neonatal period and later in life, which has also a significant public health impact because it carries an important societal economic burden. As in many cases the etiology is unknown, it is important to identify environmental factors that may be involved in the occurrence of this condition. In this review, we report all the studies published in PubMed and Scopus databases from January 1992 to January 2019, accessible as full-text articles, written in English, including clinical studies, original studies, and reviews.
View Article and Find Full Text PDFRecently, Poly-ADP-Ribose Polymerase (PARP) inhibitors are one of the most intensively studied group of antiblastic agents for the management of recurrent ovarian cancer. Among this family, Olaparib was the first to be approved by European Medicines Agency as maintenance therapy post-response to platinum-based chemotherapy for recurrent ovarian cancer in women with deleterious BRCA1/2 mutation. Following that, the Food and Drug Administration (FDA) approved Olaparib monotherapy as fourth or later line of treatment in advanced ovarian cancer with deleterious germ-line BRCA1/2 mutation.
View Article and Find Full Text PDFThe choice of treatment in case of ovarian endometriomas is one of the most discussed topics in Reproductive Medicine. Management options include expectancy, medical treatment, surgery, in vitro fertilization (IVF), or a combination of the above. The main presenting symptom, i.
View Article and Find Full Text PDF